Quarterly report [Sections 13 or 15(d)]

Segment Information

v3.25.2
Segment Information
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Information

9. Segment Information

 

The Company operates and manages its business as one reportable and operating segment dedicated to the research and development Company’s novel orally administered antiviral influenza candidate. The measure of segment assets is reported on the balance sheet as total consolidated assets. In addition, the Company manages the business activities on a consolidated basis.

 

The Company’s CODM reviews financial information presented on a consolidated basis and decides how to allocate resources based on net income (loss).

 

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM (table in thousands):

 

    2025     2024  
    Six months ended June,  
    2025     2024  
Revenue   $ -     $ -  
                 
Less:                
Research and development     2,015       6,394  
Salaries and personnel costs     783       1,308  
Insurance     126       158  
Stock-based compensation     166       306  
Operating expenses     1,359       1,440  
Other income     (93 )     (307 )
Net loss   $ 4,356     $ 9,299